早期中轴型脊柱关节炎持续缓解后塞妥珠单抗剂量递减的维持策略
C-OPTIMISE 是一项两部分、多中心 3b 期研究,纳入早期活动性中轴型脊柱关节炎成人患者,开放标签诱导期接受塞妥珠单抗 200 mg 每 2 周治疗 48 周,持续缓解者随机进入双盲维持期,比较全剂量、减剂量与安慰剂撤退。结果显示减剂量组与全剂量组无 flare 比例相近,均显著高于安慰剂组,提示持续缓解后可减量但不应完全停药。
要点
- 早期 axSpA 持续缓解者减剂量维持无 flare 比例与全剂量相近。
- 塞妥珠单抗完全撤退后 flare 风险高,不应停药。
- 放射学与非放射学 axSpA 患者的应答具有可比性。
核心结论
- 早期 axSpA 患者在第 48 周达到持续缓解后可减少塞妥珠单抗维持剂量。
- 由于停药后 flare 风险高,不应完全停用塞妥珠单抗。
研究设计与样本
- C-OPTIMISE 为两部分、多中心 3b 期研究,纳入早期活动性 axSpA 成人患者(放射学或非放射学)。
- 开放标签诱导期 48 周接受塞妥珠单抗 200 mg 每 2 周,持续缓解者随机进入 48 周双盲维持期。
主要发现
- 第 48 周 43.9%(323/736)患者达到持续缓解,其中 313 例被随机分组。
- 第 48 至 96 周,全剂量组、减剂量组与安慰剂组无 flare 比例分别为 83.7%(87/104)、79.0%(83/105)和 20.2%(21/104)。
- 两个塞妥珠单抗组与安慰剂组比较的 p<0.001。
- 放射学与非放射学 axSpA 患者的应答具有可比性。
关键数值与推荐
- 持续缓解定义为第 32/36 周和第 48 周 ASDAS<1.3。
- flare 定义为连续两次访视 ASDAS≥2.1 或任意时间点 ASDAS>3.5。
- 全剂量为塞妥珠单抗 200 mg 每 2 周,减剂量为 200 mg 每 4 周。
临床怎么用
- 对达到持续缓解的早期 axSpA 患者可考虑塞妥珠单抗减剂量维持。
- 应避免完全停用塞妥珠单抗,以降低 flare 风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axSpA. METHODS: C-OPTIMISE was a two-part, multicentre phase 3b study in adults with early active axSpA (radiographic or non-radiographic). During the 48-week open-label induction period, patients received CZP 200 mg every 2 weeks (Q2W). At Week 48, patients in sustained remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 at Weeks 32/36 and 48) were randomised to double-blind CZP 200 mg Q2W (full maintenance dose), CZP 200 mg every 4 weeks (Q4W; reduced maintenance dose) or placebo (withdrawal) for a further 48 weeks. The primary endpoint was remaining flare-free (flare: ASDAS ≥2.1 at two consecutive visits or ASDAS >3.5 at any time point) during the double-blind period. RESULTS: At Week 48, 43.9% (323/736) patients achieved sustained remission, of whom 313 were randomised to CZP full maintenance dose, CZP reduced maintenance dose or placebo. During Weeks 48 to 96, 83.7% (87/104), 79.0% (83/105) and 20.2% (21/104) of patients receiving the full maintenance dose, reduced maintenance dose or placebo, respectively, were flare-free (p<0.001 vs placebo in both CZP groups). Responses in radiographic and non-radiographic axSpA patients were comparable. CONCLUSIONS: Patients with early axSpA who achieve sustained remission at 48 weeks can reduce their CZP maintenance dose; however, treatment should not be completely discontinued due to the high risk of flare following CZP withdrawal. TRIAL REGISTRATION NUMBER: NCT02505542, ClinicalTrials.gov.
引用
- Landewé RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020. PMID: 32381562. doi:10.1136/annrheumdis-2019-216839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。